Market Cap: 28.4543B; Large Cap
P/E Ratio: 31.65; Fwd: 28.82
EPS (TTM): $2.33
Div. Yield: N/A

DX

DXCMNASDAQ— DexCom Inc Price & Analysis

DexCom Inc

HEALTHCARE — MEDICAL DEVICES

$78.19

+$1.57+2.05%

Market Cap: 28.4543B; Large Cap
P/E Ratio: 31.65; Fwd: 28.82
EPS (TTM): $2.33
Div. Yield: N/A

Technical Summary

RSI (14)72.86Overbought

SMA (50)$65.10Bullish

SMA (200)$67.61Bullish

MACD3.3730Bullish

Bollinger$58.30 – $81.33Mid

Stochastic85.98Overbought

Theo Outlook

DexCom Inc (DXCM) presents a bullish thesis with a market cap of $28.08B, trailing P/E of 31.23, EPS of $2.33, and 15% year-over-year revenue growth to $4.82B TTM, supported by 19.3% profit margins and 92.2% quarterly earnings growth. The stock trades at a forward P/E of 28.65 with an analyst target of $82.79, reflecting strong positioning in the diabetes management space.

Key catalysts include continued CGM system adoption, international market expansion, and earnings momentum from new product launches and manufacturing scale-up in Mesa, Arizona, driving 15% revenue growth and 92% EPS expansion. Healthcare sector tailwinds and rising diabetes prevalence further support double-digit growth.

Risks include regulatory hurdles for medical devices, intense competition from Abbott and Medtronic, and macro headwinds like reimbursement changes or economic slowdowns; these are mitigated by DexCom's 35.6% ROE, 1.4 beta, and diversified global operations. Analysis generated by HeyTheo AI based on SEC filings, earnings transcripts, and market data.

Theo Outlook

DexCom Inc (DXCM) presents a bullish thesis with a market cap of $28.08B, trailing P/E of 31.23, EPS of $2.33, and 15% year-over-year revenue growth to $4.82B TTM, supported by 19.3% profit margins and 92.2% quarterly earnings growth. The stock trades at a forward P/E of 28.65 with an analyst target of $82.79, reflecting strong positioning in the diabetes management space.

Key catalysts include continued CGM system adoption, international market expansion, and earnings momentum from new product launches and manufacturing scale-up in Mesa, Arizona, driving 15% revenue growth and 92% EPS expansion. Healthcare sector tailwinds and rising diabetes prevalence further support double-digit growth.

Risks include regulatory hurdles for medical devices, intense competition from Abbott and Medtronic, and macro headwinds like reimbursement changes or economic slowdowns; these are mitigated by DexCom's 35.6% ROE, 1.4 beta, and diversified global operations. Analysis generated by HeyTheo AI based on SEC filings, earnings transcripts, and market data.

Company Overview

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.

Fundamental Snapshot

Revenue: 4.8179B
EBITDA: 1.2923B
Gross Profit: 2.9632B
Operating Margin: 21.4%
Profit Margin: 19.3%
ROE: 35.6%
Book Value: $7.66
Beta: 1.398
52-Wk High: $89.98
52-Wk Low: $54.11
Avg Volume: 6.1204M
PEG Ratio: 1.375

Frequently Asked Questions

What is DexCom's business model and primary revenue sources?

DexCom develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management, generating $4.82B TTM revenue primarily from CGM sensor sales and related hardware with 19.3% profit margins.

What are DexCom's key competitive advantages?

DexCom holds strong competitive advantages through its proprietary CGM technology, 35.6% return on equity, global manufacturing in Arizona, and 102.7% institutional ownership, differentiating it in the medical devices sector.

What are the main risks for DXCM investors?

Trading Data

Open: $77.48
Previous Close: $76.62
Day Range: $76.5 – $78.8176
Volume: 5.424M
Shares Outstanding: 385.873M
Analyst Target: $82.79

Related Assets

Intuitive Surgical Inc

Vertex Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

$600.66

-2.30%

Get Deeper Analysis

Ask Theo anything about DXCM — earnings, valuation, technicals, or portfolio fit.

Try HeyTheo Free

Company Overview

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.

Fundamental Snapshot

Revenue: 4.8179B
EBITDA: 1.2923B
Gross Profit: 2.9632B
Operating Margin: 21.4%
Profit Margin: 19.3%
ROE: 35.6%
Book Value: $7.66
Beta: 1.398
52-Wk High: $89.98
52-Wk Low: $54.11
Avg Volume: 6.1204M
PEG Ratio: 1.375

Frequently Asked Questions

What is DexCom's business model and primary revenue sources?

DexCom develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management, generating $4.82B TTM revenue primarily from CGM sensor sales and related hardware with 19.3% profit margins.

What are DexCom's key competitive advantages?

DexCom holds strong competitive advantages through its proprietary CGM technology, 35.6% return on equity, global manufacturing in Arizona, and 102.7% institutional ownership, differentiating it in the medical devices sector.

What are the main risks for DXCM investors?

Key risks include regulatory approvals for medical devices, competition from Abbott and Medtronic, and macro factors like reimbursement changes; these are offset by 92.2% quarterly earnings growth and a $82.79 analyst target price.

What is DexCom's growth outlook and recent performance?

DexCom shows strong growth with 15% YoY revenue growth to $4.82B TTM, 92.2% quarterly earnings growth, EPS of $2.33, and a forward P/E of 28.65, positioning it for continued expansion in diabetes care.

Does DXCM pay dividends and what is its valuation?

DXCM does not pay dividends (yield null); it trades at a trailing P/E of 31.23, market cap of $28.08B, and 52-week range of $54.11-$89.98, with next earnings expected around the March 2026 quarter end.

DX